Modeling Compound-Induced Fibrogenesis In Vitro Using 3D Bioprinted Human Liver Tissues
Presented live on July 28, 2016
Presenter: Leah Norona, Doctoral Candidate at UNC Chapel Hill
Moderator: Jeff Irelan, Ph.D., Director, Scientific Applications, Organovo
Compound-induced hepatotoxicity leading to fibrosis remains a challenge for human risk assessment. Latency to detection and lack of early biomarkers make it difficult to characterize the dynamic and complex intercellular interactions that occur during progressive liver injury. Thus in vitro systems that recapitulate this cellular complexity in a three dimensional context offer advantages over simple monoculture systems with respect to predictive modeling. Through the incorporation of key architectural features and primary cell types, 3D bioprinted liver can be maintained in culture for greater than four weeks, making it an ideal platform for studying phenotypes that arise during recurring exposure. Here, we discuss the utility of NovoView™ Human Liver Tissue for modeling chronic compound exposure using fibrosis as a case study and provide a comprehensive approach to examine key initiating events and progression of tissue injury.
Leah Norona received her B.S. in Pharmacology from the State University of New York at Stony Book, and is currently pursuing her Ph.D. in Toxicology at the University of North Carolina at Chapel Hill. Leah’s research interests involve understanding the fundamental mechanisms underlying drug and chemical-induced toxicity, specifically chronic liver injury leading to fibrosis.